Navigation Links
Infinata’s BioPharm Insight Signs 200th Media Partner, Inaugurates Advertising Program
Date:2/14/2013

Norwood, MA (PRWEB) February 14, 2013

Infinata’s BioPharm Insight™ announced it signed its 200th media partner and unveiled an advertising program designed to help partners increase attendance at their events. BioPharm Insight offers the global biopharmaceutical community a unique combination of business intelligence, market analytics, key industry contacts, and award-winning independent investigative journalism.

Infinata partners with businesses and organizations within all biopharma and wealth sectors to promote industry-changing events such as conferences and symposia. Media partners include:

  •     Biotechnology Industry Organization (BIO)
  •     Drug Information Association (DIA)
  •     The Conference Forum
  •     EBD Group
  •     SMi Group
  •     HealthNetwork Communications
  •     Worldwide Business Research (WBR)
  •     Partnerships in Clinical Trials
  •     The Financial Times
  •     ExL Pharma
BioPharm Insight Inaugurates Advertising Program

Industry professionals rely on BioPharm Insight’s newsletter program to stay ahead of their competition with updates on proprietary forward-looking intelligence, clinical trial news, and upcoming industry conferences. BioPharm Insight has created a new opportunity to get in front of these influential executives with a completely redesigned newsletter providing optimal space for companies to promote their solutions.

Jim Davis, Infinata’s Global Head of Sales for its BioPharm Suite, said, “Media partners and advertisers rely on BioPharm Insight to develop awareness and reach the most influential decision makers in the biopharma industry.”

T
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Infinata’s BioPharm Insight™ Achieves Record Growth in 2012
2. Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Presentation Scheduled for Monday, February 11th at 2:30 PM ET
3. Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2013
4. Infinata's BioPharm Clinical™ to Present Session on Improving Investigator Selection at CHI’s Summit for Clinical Operations (SCOPE) on February 6 in Miami, FL
5. Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer
6. Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2013 On February 4, 2013
7. BioPharm Systems to Host Webinar on an Add-On Solution for Oracle Clinical
8. BioPharm Systems to Host Webinar on Self-service Account Management for Oracle Clinical, Remote Data Capture, and Thesaurus Management System
9. Array BioPharma Provides Updates On Clinical Data At The 2012 American Society Of Hematology Meeting
10. TransCelerate BioPharma Inc. Appoints Dalvir Gill as Chief Executive Officer
11. Array BioPharma Announces Exercise And Closing Of Underwriters Over-Allotment Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Mass. , July 30, 2015   ... solutions for the interpretation and analysis of genomic ... Matthew Fischer has joined the company as ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... capabilities to integrate, interpret, analyze and explore complex ...
(Date:7/30/2015)... , July 30, 2015 ... by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, ... & Development, Preclinical, Clinical Trial), by End Users - ... Market is expected to reach USD 2,107.99 million by ... CAGR of 15.29%. Browse more than ...
(Date:7/30/2015)...   Senomyx , Inc. (NASDAQ: SNMX ), ... discover, develop, and commercialize novel flavor ingredients for the ... results for the second quarter 2015. ... on track to achieve our commercial and financial goals," ... the Company. "Since our last quarterly earnings report, our ...
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes are against ... were $697 million compared to $701 million in the ... and changes in foreign currency exchange rates decreased sales ... , By business unit, organic sales growth was 6% ... Commercial. , Reported diluted EPS was $0.98 compared ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... Integrated Global Services, CAMBRIDGE, Mass., April 1, ... a new name, Abt Bio-Pharma Solutions, Inc., a,wholly ... will continue to,provide custom strategic, research and communication ... industries,utilizing a team approach that blends decades of ...
... Derma Sciences,Inc (OTC Bulletin Board: DSCI), a provider of ... $34.1 million, an increase of 22 percent,over the $27.9 ... 34,percent, but due primarily to the costs of bringing ... marketing and sales staffs, the,Company reported a loss of ...
... 1, 2008 Champions,Biotechnology, Inc. (OTC Bulletin Board: ... preclinical platforms and tumor specific data to,enhance the ... of new,Board of Directors members and the formation ... expand its operations., Abba David Poliakoff and ...
Cached Biology Technology:Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc. 2Derma Sciences Reports Fourth Quarter Year-End Results for 2007 2Derma Sciences Reports Fourth Quarter Year-End Results for 2007 3Derma Sciences Reports Fourth Quarter Year-End Results for 2007 4Derma Sciences Reports Fourth Quarter Year-End Results for 2007 5Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team 2Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team 3Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team 4Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team 5Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team 6Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team 7Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team 8
(Date:6/30/2015)... YORK , June 30, 2015 To bolster ... security provider HYPR Corp. announced today the addition of two ... will serve as board advisor and David Raviv ... the team underscore HYPR Corp.,s commitment to providing the most ... Dimitri Sirota co-founded Layer 7 Technologies, a provider ...
(Date:6/25/2015)... DALLAS , June 25, 2015 ... report "Fingerprint Sensors Market by Type (Swipe & Area), Technology, ... (Mobile, Government, Healthcare, Commercial Security & Others) & ... published by marketsandmarkets, the said market is expected ... CAGR of 17.1%. Browse 76 ...
(Date:6/24/2015)... 2015 This report provides market analysis of ... years. It contains an analysis of the drivers, challenges, ... impact from the short, medium, and long term perspective ... market, and technology trends that currently, prevail in the ... authorities to efficiently manage the increasing marine traffic and ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... non-coding RNAs are small molecules that help control ... they have emerged as disease biomarkers. miRNA profiles ... cancers of unknown primary origin, determine prognosis, monitor ... tractable, diagnostic methods for monitoring miRNA expression in ...
... scientists have focused among other factors on drugs ... is the accumulation of A-beta that causes the known plaques ... formation of A-beta is APP. Alessia Soldano and Bassem Hassan ... APPL the fruit-fly version of APP in the ...
... Automated conserved noncoding sequence (CNS) discovery reveals ... Within the genome of each species, there are thousands ... and sequence over millions of years, but do not code ... conserved noncoding sequences (CNSs), are known to regulate the expression ...
Cached Biology News:A new strategy required in the search for Alzheimer's drugs? 2Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3
Puromycin resistance gene (pac), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
...
... is designed to allow neomycin/kanamycin selection ... The loxP-PGK-gb2-neo-loxP template encodes the neomycin/kanamycin ... promoter (gb2) for expression of kanamycin ... promoter (PGK) for expression of neomycin ...
... These precision 5mm diameter, 7 inch long PYREX ... for compatibility with ground joints, valves, and vacuum ... spectrometers running from 300 to 500MHz. They have ... I.D. of 4.20 + 0.013-0.000mm. These NMR tubes ...
Biology Products: